



1

SEQUENCE LISTING

<110> Ball, Kathryn L
Lane, David P

<120> Methods and Means for Inhibition of CDK4 Activity

<130> CCI-007US

<140> US 09/180,269

<141> 1999-07-08

<150> PCT/GB97/01250

<151> 1997-05-08

<150> GB 9609521.1

<151> 1996-05-08

<150> GB 9621314.5

<151> 1996-10-09

<160> 28

<170> PatentIn Ver. 2.1

<210> 1

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 1

Met Ser Glu Pro Ala Gly Asp Val Arg Gln Asn Pro Cys Gly Ser Lys
1 5 10 15

Ala Cys Arg Arg
20

<210> 2

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 2

Lys Ala Cys Arg Arg Leu Phe Gly Pro Val Asp Ser Glu Gln Leu Ser
1 5 10 15

Arg Asp Cys Asp
20

B1

<210> 3
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 3
 Ser Arg Asp Cys Asp Ala Leu Met Ala Gly Cys Ile Gln Glu Ala Arg
 1 5 10 15

Glu Arg Trp Asn
 20

<210> 4
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 4
 Arg Glu Arg Trp Asn Phe Asp Phe Val Thr Glu Thr Pro Leu Glu Gly
 1 5 10 15

Asp Phe Ala Trp
 20

<210> 5
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 5
 Gly Asp Phe Ala Trp Glu Arg Val Arg Gly Leu Gly Leu Pro Lys Leu
 1 5 10 15

Tyr Leu Pro Thr
 20

B!
 Cont.

<210> 6
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 6
 Leu Tyr Leu Pro Thr Gly Pro Arg Arg Gly Arg Asp Glu Leu Gly Gly
 1 5 10 15

Gly Arg Arg Pro
 20

<210> 7
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 7
 Gly Gly Arg Arg Pro Gly Thr Ser Pro Ala Leu Leu Gln Gly Thr Ala
 1 5 10 15

Glu Glu Asp His
 20

<210> 8
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 8
 Ala Glu Glu Asp His Val Asp Leu Ser Leu Ser Cys Thr Leu Val Pro
 1 5 10 15

Arg Ser Gly Glu
 20

<210> 9
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 9
 Pro Arg Ser Gly Glu Gln Ala Glu Gly Ser Pro Gly Gly Pro Gly Asp
 1 5 10 15

Ser Gln Gly Arg
 20

<210> 10
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 10
 Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg
 1 5 10 15

Leu Ile Phe Ser
 20

<210> 11
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 11
 Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser
 1 5 10 15

Lys Arg Lys Pro
 20

<210> 12
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Motif

<400> 12
 Arg Arg Leu Ile Phe
 1 5

<210> 13
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Motif

<400> 13
 Lys Arg Arg Leu Ile Phe Ser Lys
 1 5

<210> 14
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> SITE
 <222> (2)..(3)
 <223> Xaa may be any amino acid

<220>
 <221> SITE
 <222> 6, 8
 <223> Xaa may be hydrophobic

<220>
 <221> SITE
 <222> 1, 9
 <223> Residue may be absent or different, ie another
 amino acid

<220>
 <223> Description of Artificial Sequence: General
 formula

<400> 14
 Lys Xaa Xaa Arg Arg Xaa Phe Xaa Pro
 1 5

<210> 15
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Carrier
 peptide

<400> 15
 Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
 1 5 10 15

<210> 16
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 16
 Pro Arg Ser Gly Glu Gln Ala Glu Gly Ser Pro Gly Gly Pro Gly Asp
 1 5 10 15

Ser Gln Gly Arg
 20

<210> 17
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthesised

<400> 17
 Glu Gln Ala Glu Gly Ser Pro Gly Gly Pro Gly Asp Ser Gln Gly Arg
 1 5 10 15

Lys Arg Arg Gln
 20

<210> 18
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 18
 Gly Ser Pro Gly Gly Pro Gly Asp Ser Gln Gly Arg Lys Arg Arg Gln
 1 5 10 15

Thr Ser Met Thr
 20

<210> 19
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 19
 Gly Pro Gly Asp Ser Gln Gly Arg Lys Arg Arg Gln Thr Ser Met Thr
 1 5 10 15

Asp Phe Tyr His
 20

<210> 20
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 20
 Ser Gln Gly Arg Lys Arg Arg Gln Thr Ser Met Thr Asp Phe Tyr His
 1 5 10 15

Ser Lys Arg Arg
 20

<210> 21
 <211> 20
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 21
 Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser
 1 5 10 15
 Lys Arg Lys Pro
 20

<210> 22
 <211> 16
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 22
 Asp Phe Tyr His Ser Lys Arg Arg Leu Ile Phe Ser Lys Arg Lys Pro
 1 5 10 15

<210> 23
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Truncated
 peptide

<400> 23
 Lys Arg Arg Leu Ile Phe Ser Lys
 1 5

<210> 24
 <211> 36
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 24
 Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg
 1 5 10 15
 Leu Ile Phe Ser Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met
 20 25 30
 Lys Trp Lys Lys
 35

<210> 25
 <211> 24
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 25
 Lys Arg Arg Leu Ile Phe Ser Lys Arg Gln Ile Lys Ile Trp Phe Gln
 1 5 10 15
 Asn Arg Arg Met Lys Trp Lys Lys
 20

<210> 26
 <211> 30
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthesised

<400> 26
 Arg Gln Thr Ser Met Thr Asp Phe Tyr His Ser Lys Arg Arg Arg Gln
 1 5 10 15
 Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
 20 25 30

<210> 27
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthesised

<400> 27
Gln Thr Ser Met Thr Asp Phe Tyr
1 5

<210> 28
<211> 20
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthesised

<400> 28
Lys Arg Arg Gln Thr Ser Ala Thr Asp Phe Tyr His Ser Lys Arg Arg
1 5 10 15

Leu Ile Phe Ser
20

B1
Cont